Skip to main content

STERIS Value Stock - Dividend - Research Selection

Steris

ISIN: IE00BFY8C754 , WKN: A2PGLV

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

2026-05-26
STERIS has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Reasons to Retain STE Stock in Your Portfolio for Now

2026-05-22
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.

Tracking Al Gore's Generation Investment Management Portfolio - Q1 2026 Update

2026-05-20
Generation IM Q1 2026 13F: portfolio drops to $11.16B; top holdings MSFT, AMZN & GOOGL; big buys/sells and new picks.

The 5 Most Interesting Analyst Questions From STERIS’s Q1 Earnings Call

2026-05-19
STERIS delivered Q1 results that met Wall Street’s revenue expectations, with the market reacting positively to the company’s performance. Management pointed to steady procedure volume growth in the U.S. and continued expansion in its Healthcare and Life Sciences segments as key drivers. CEO Dan Carestio cited strong service revenue, improved consumables growth, and a stabilizing capital equipment business, while also acknowledging external pressures such as inflation and tariffs. Notably, sever

Q1 Earnings Highs And Lows: STERIS (NYSE:STE) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks

2026-05-17
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STERIS (NYSE:STE) and the best and worst performers in the surgical equipment & consumables - diversified industry.

STE Q1 Deep Dive: Margin Expansion and Service Growth Offset Cost Pressures

2026-05-16
Medical equipment and services company Steris (NYSE:STE). met Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.3% year on year to $1.59 billion. Its non-GAAP profit of $2.83 per share was 0.7% below analysts’ consensus estimates.

STERIS Q4 Earnings Call Highlights

2026-05-15
STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027. Senior Vice P

A Look At STERIS (STE) Valuation After Recent Share Price Weakness

2026-05-14
Recent share performance and business scale STERIS (STE) has drawn investor attention after a period in which the stock declined about 6% over the past month and roughly 14% over the past 3 months, prompting closer review of its fundamentals. The company reports annual revenue of US$5.94b and net income of US$782.3m, with operations spanning Healthcare, Applied Sterilization Technologies and Life Sciences, and a market value of about US$20.68b. See our latest analysis for STERIS. At a share...

Keybanc Maintains Overweight on Steris, Lowers Price Target to $269

2026-05-13
Keybanc analyst Brett Fishbin maintains Steris (NYSE:STE) with a Overweight and lowers the price target from $291 to $269.

What To Expect From STERIS’s (STE) Q1 Earnings

2026-05-13
Medical equipment and services company Steris (NYSE:STE). will be reporting results this Monday after the bell. Here’s what you need to know.